Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the...
Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial
About this item
Full title
Author / Creator
Publisher
New York, NY: Mosby, Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Mosby, Inc
Subjects
More information
Scope and Contents
Contents
Despite advances in antithrombotic therapies and invasive technology, the risk of recurrent ischemic complications in patients with non–ST-elevation acute coronary syndromes (NSTE-ACSs) remains substantial. Ranolazine is a novel agent that inhibits the late sodium current thereby reducing cellular sodium and calcium overload and has been shown to r...
Alternative Titles
Full title
Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1504621818
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1504621818
Other Identifiers
ISSN
0002-8703
E-ISSN
1097-6744
DOI
10.1016/j.ahj.2006.06.016
